Moderna Therapeutics, a clinical-stage biotechnology firm that develops messenger RNA (mRNA) therapeutics and vaccines, has secured $500 million in a round participated by Singapore-based EDBI and Sequoia Capital China, it announced in a release.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
